Product Description: IMD-0354 (IKK2 Inhibitor V) is a selective IKKβ inhibitor which inhibits NF-κB activity[1]. IMD0354 inhibits TNF-α induced NF-κB transcription activity with an IC50 of 1.2 uM[2].
Applications: Cancer-Kinase/protease
Formula: C15H8ClF6NO2
References: [1]Tanaka A, et al. A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood. 2005 Mar 15;105(6):2324-31./[2]Li YR, et al. Study of the inhibitory effects on TNF-α-induced NF-κB activation of IMD0354 analogs. Chem Biol Drug Des. 2017 Dec;90(6):1307-1311./[3]Tanaka A, et al. A new IkappaB kinase beta inhibitor prevents human breast cancer progression through negative regulation of cell cycle transition. Cancer Res. 2006 Jan 1;66(1):419-26./[4]Lennikov A, et al. Amelioration of endotoxin-induced uveitis treated with an IκB kinase β inhibitor in rats. Mol Vis. 2012;18:2586-97.
CAS Number: 978-62-1
Molecular Weight: 383.67
Compound Purity: 99.51
Research Area: Cancer
Solubility: DMSO : ≥ 100 mg/mL/H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C)
Target: IKK
English
Deutsch
